Novotech has announced the appointment of Dr. Anand Tharmaratnam as its new Chief Executive Officer, marking a major leadership milestone for the Singapore-headquartered clinical research organisation. Effective January 2026, the appointment reflects Novotech’s ambition to strengthen its global position as a leading contract research organisation (CRO) focused on biotechnology and advanced clinical development. Dr. Tharmaratnam steps into the role at a time when the global life sciences sector is undergoing rapid expansion, driven by innovation in therapeutics, precision medicine, and complex clinical trials.
Dr. Tharmaratnam brings nearly three decades of experience across biotechnology, pharmaceuticals, and clinical research services. Widely respected in the global life sciences ecosystem, he has built a career at the intersection of science, strategy, and operational leadership. Prior to his appointment as CEO, he served in senior governance and leadership roles, where he played a key part in shaping long-term strategy, global expansion, and organisational culture. His transition into the chief executive role is seen as both a continuation of Novotech’s strategic direction and a signal of renewed momentum.
Novotech has grown steadily into a globally recognised CRO, supporting biotechnology companies from early-phase development through to late-stage clinical trials. With a strong presence across Asia-Pacific, North America, and Europe, the company is known for its scientific depth, regulatory expertise, and ability to manage complex, multi-region trials. Dr. Tharmaratnam’s appointment aligns with Novotech’s focus on scaling its operations while maintaining high scientific and ethical standards in clinical research.
As CEO, Dr. Tharmaratnam is expected to prioritise global growth while deepening Novotech’s core strengths in biotechnology-focused clinical development. The CRO sector is becoming increasingly competitive, with sponsors demanding faster timelines, greater data integrity, and advanced technological integration. Under his leadership, Novotech is likely to invest further in digital trial solutions, data analytics, and patient-centric trial design to enhance efficiency and outcomes.
Another key focus area under the new CEO is talent and organisational capability. Clinical research is a highly specialised field, dependent on skilled professionals across regulatory affairs, biostatistics, medical writing, and project management. Dr. Tharmaratnam has consistently emphasised the importance of building strong teams and leadership pipelines, ensuring that scientific excellence is matched by operational discipline and collaborative culture.
The appointment also underscores Singapore’s growing role as a global hub for life sciences and clinical research leadership. With its strong regulatory framework, research infrastructure, and access to Asia-Pacific markets, Singapore provides an ideal base for Novotech’s global strategy. Dr. Tharmaratnam’s leadership from Singapore reinforces the city-state’s position as a centre for decision-making in the global biotechnology ecosystem.
Industry observers note that Dr. Tharmaratnam’s scientific background gives him a unique advantage in leading a research-driven organisation. His ability to engage with biotech founders, investors, regulators, and research teams is expected to strengthen Novotech’s relationships with sponsors seeking a trusted, long-term CRO partner. In an era where clinical trials are becoming more complex and capital-intensive, such credibility at the leadership level is increasingly valuable.
As Dr. Anand Tharmaratnam takes over as CEO, Novotech enters a new chapter defined by ambition, innovation, and global reach. His leadership is expected to guide the company through the next phase of expansion while staying true to its mission of advancing clinical research and accelerating the development of life-changing therapies worldwide.
